Clinical Trials Browser

Adenocarcinoma, Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Glandular and Epithelial, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT00005807 2018-10-09

BMS-247550

Phase 1 Completed

40 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male

NCT00030706 2018-09-28

Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Completed

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00627978 2018-06-26

Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

Phase 2 Completed

15 enrolled 6 charts

Breast

Breast Neoplasms

NCT01012362 2017-12-28

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Phase 1 Terminated

31 enrolled 12 charts

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT00789581 2017-07-02

TITAN

Phase 3 Completed

614 enrolled 10 charts

Breast

Breast Neoplasms

NCT00637897 2017-05-30

Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1 Completed

24 enrolled

Breast

Breast Neoplasms

NCT00998738 2016-02-04

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

Phase 3 Terminated

1 enrolled 1 chart

Breast

Breast Neoplasms, Pain

NCT00884676 2015-10-09

Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors

Phase 1 Completed

36 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01057212 2015-09-07

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

6 enrolled

Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT00821886 2014-12-22

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Phase 2 Completed

60 enrolled 5 charts

Breast

Breast Neoplasms

NCT00825734 2014-12-22

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Phase 1/2 Completed

83 enrolled 8 charts

Breast

Breast Neoplasms

NCT00751868 2014-12-17

GIM9

Phase 2 Completed

47 enrolled

Breast

Breast Neoplasms

NCT00924352 2014-10-13

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Phase 1/2 Completed

56 enrolled 14 charts

Breast

Breast Neoplasms

NCT01170871 2014-05-21

Ixabepilone and Pemetrexed/Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Advanced Solid Tumors

NCT00022477 2013-09-05

BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Phase 2 Completed

24 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00033306 2013-08-05

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Terminated

2 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00017056 2013-06-18

BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT00020904 2013-06-18

BMS-247550 in Treating Women With Metastatic Breast Cancer

Phase 2 Completed

Breast

Breast Neoplasms

NCT00804310 2012-03-28

UCDCC#207

Phase 1 Terminated

5 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00998101 2012-03-06

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01454479 2011-10-19

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Phase 1 Unknown

24 enrolled

Gynecologic

Endometrial Neoplasms

NCT00790894 2011-05-18

HIT

Phase 2 Terminated

64 enrolled

Breast

Breast Neoplasms